Mindray (300760) Q2 2026 earnings summary

Executive summary

• Revenue for H1 2026 reached RMB 17.75 billion, up 6.00% year-over-year; net profit attributable to shareholders was RMB 4.80 billion, down 5.37% year-over-year.

• International business accounted for 53% of total revenue, with international revenue up 13.67% year-over-year; domestic revenue declined 1.61%.

• Adjusted for currency effects, international revenue grew 18.42% in USD terms; excluding FX, net profit grew 8.68% year-over-year.

• Cash flow from operations increased 24.35% year-over-year to RMB 4.88 billion.

Financial highlights

• Gross margin remained robust across segments: IVD 61.06%, Life Info & Support 58.88%, Imaging 59.12%, Emerging Businesses 65.03%.

• Operating expenses rose modestly; R&D investment was RMB 1.78 billion, 10.02% of revenue.

• Net assets attributable to shareholders increased 6.47% from year-end 2025 to RMB 40.56 billion.

• Basic and diluted EPS were RMB 3.9584, down 5.39% year-over-year.

• Asset-liability ratio improved to 25.47%.

Outlook and guidance

• International business expected to maintain rapid growth, led by Europe, Latin America, and Asia-Pacific.

• Domestic business anticipated to return to positive growth in 2026, with further acceleration in 2027 and beyond.

• Company will continue to invest in R&D, expand high-value consumables, and pursue global M&A for long-term growth.